Commercial Lines

EY's global outlook finds generally positive conditions for 2015, but uses of technology will separate the winners from the losers.

The ProPublica series makes valid points about problems in workers' comp but misses some context and omits many, many positive stories.

Drug formularies hold great promise to control costs and improve treatment, but they must be phased in carefully, over years.

In workers' comp, medical costs are more than 60% of claim cost and continue to climb, but rethinking how to use data can make inroads.

Predictive analytics encourage employers to fast-track many workers' comp claims, but they should presume problems are lurking.

Drug prices, under physician dispensing, have come down significantly after reforms but remain much higher than at retail pharmacies.

As workers' comp claims dwindle, providers should offer "absence management" -- handling loss of work time for any reason, not just injury.

With so much contention appearing in what was supposed to be a no-fault system, is it time to redesign work comp from scratch?